Quick Menu

New StripAssay from Viennalab : NRAS

A new StripAssay, supplementing our range of cancer pharmacogenomic products (KRAS, BRAF, EGFR, FCGR), is being released: The NRAS StripAssay (Cat.# 5-610) detects 12 different mutations within the critical codons 12, 13 and 61 of the NRAS gene. It is capable of detecting mutations at a level of 1 percent in a background of wild-type NRAS.

The effectiveness of the anti-EGFR monoclonal antibodies cetuximab (Erbitux) and panitumumab (Vectibix) is very well established in KRAS non-mutated colorectal cancer (CRC) patients. Patients that harbour KRAS mutations, on the other hand, have been found to be resistant to those therapies. NRAS, another member of the ras gene family, is also mutated in CRC and various other tumors. Recently the PRIME Study showed that not only KRAS, but also NRAS mutations, will predict a lack of response to panitumumab. AMGEN, the manufacturer of Vectibix, meanwhile released a safety note recommending NRAS testing before starting panitumumab therapy.

  All News
New StripAssay from Viennalab : NRAS
Viennalab’s relased EGFR StripAssay
Viennalab’s relased new BRAF 600/601 StripAssay
4(four) new Strip Assays from Viennalab;
Two New Kits from Viennalab :(1.) PGX-TPMT StripAssay (Cat.# 4-740), Lactose Intolerance StripAssay (Cat.# 4-300)
Viennalab has introduced two new strip assays :BRAF and KRAS-BRAF StripAssay
Medical Genetics Association hosted a symposium with the topic of ‘Endocrinology and Genetics’ between 8th and 10th of October 2009 in Abant, Bolu.
Tecan Profiblot T48 service training program for sub-dealer personnel has been concluded.
Invitrotek’s Izmir branch office has began its operation at the below address as of 15th of June.
Invitrotek has become the exclusive distributor of Tecan’s Profiblot product range for Turkey.

Powered by EOS